Anzeige
Mehr »
Login
Samstag, 25.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Achtung! Ist das die Krypto-Aktie des Jahres 2024 mit 700% Potential?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CVT6 | ISIN: US1420381089 | Ticker-Symbol:
NASDAQ
24.05.24
22:00 Uhr
2,970 US-Dollar
-0,040
-1,33 %
1-Jahres-Chart
CARIBOU BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
CARIBOU BIOSCIENCES INC 5-Tage-Chart

Aktuelle News zur CARIBOU BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoASTS, CRBU and DOMO are among after hour movers1
MoSBRA, GH and CRBU are among after hour movers2
16.05.Expert Ratings For Caribou Biosciences6
07.05.Caribou Biosciences, Inc. - 8-K, Current Report3
24.04.Caribou Biosciences, Inc.: Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting6
15.04.Caribou Biosciences, Inc.: Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)3
05.04.Kura Sushi Posts Upbeat Sales, Joins Caribou Biosciences, Krispy Kreme And Other Big Stocks Moving Higher In Friday's Pre-Market Session2
04.04.Caribou Biosciences received IND clearance from FDA for its lupus treatment2
04.04.Caribou Biosciences, Inc.: Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus113-- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- Driven by encouraging initial safety...
► Artikel lesen
04.04.Caribou Biosciences, Inc. - 8-K, Current Report1
19.03.Caribou Biosciences shares target raised to $24 by H.C. Wainwright6
12.03.Why Caribou Biosciences Stock Is Crashing Today12
11.03.Caribou Biosciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
11.03.Caribou Biosciences, Inc. - 10-K, Annual Report1
11.03.Caribou Biosciences, Inc. - 8-K, Current Report1
11.03.Caribou Biosciences, Inc.: Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update277-- 30th patient dosed in CB-010 ANTLER Phase 1 trial dose expansion; initial dose expansion data and RP2D to be disclosed in Q2 2024 -- -- 1st patient dosed in CB-012 AMpLify Phase 1 trial for patients...
► Artikel lesen
20.02.Precision BioSciences Enters Patent License Agreement With Caribou Biosciences7
08.01.Caribou Biosciences, Inc. - 8-K, Current Report1
07.01.Caribou Biosciences, Inc.: Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024206-- Tim Kelly to lead Caribou's technical operations strategy and execution -- -- CB-010 ANTLER Phase 1 trial initial dose expansion data and RP2D to be disclosed Q2 2024; Caribou plans to initiate...
► Artikel lesen
22.12.23Caribou Biosciences, Inc. - 8-K, Current Report3
Seite:  Weiter >>
25 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1